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Abstract
Objective to analyse the introduction of reference 
pricing systems for pharmaceuticals in malta, their 
effectiveness and adequacy to-date, and to propose 
possible improvements.   
Method a study on 18 interviewees associated 
with pharmaceutical and economical pricing policies 
was performed. a literature review analysis of the local 
published media regarding the subject was also undertaken 
to confirm personal interpretations given and to bridge 
information gaps. 
Key Findings there are two separate reference 
pricing systems in place; one for the private and another for 
the public health sector, operating via different economic 
mechanisms. reasons for resorting to such systems centred 
around the lack of access and affordability of medicines. 
this situation had emanated from an inefficient business 
environment, lack of proper government regulation 
and management and an imbalance of power between 
medicines’ suppliers, consumers and patients.  a total of 
18 respondents participated in the study. two out of the 18 
respondents considered the system successful, 6 deemed it 
unsuccessful and 7 thought the system had limited success. 
results show that reference pricing may be regarded as a 
fair and simple means of monitoring and comparing local 
medicine prices with those of other countries. reference 
pricing systems do not cater for many of the problems 
associated with such pricing.  
Conclusions reference pricing cannot be taken 
out of context in an integrated pharmaceutical system. 
the situation must be tackled holistically to address the 
real issues hindering the establishment of fair prices of 
medicines for maltese consumers. policy systems should be 
constructed in accordance with malta’s particular political, 
economic and cultural requirements in line with local and 
European union (Eu) legislation.  
Keywords  pharmacoeconomics, reference pricing, 
pharmaceutical pricing policy.
Introduction  
 
health policy systems represent a challenge for every 
government due to existing competing interests. 
governments must safeguard public health, secure patient 
access to safe and effective medicines and contain the 
health expenditure within the required limits. industrial 
policy obligations must also be considered. 
Economic sustainability measures can be directed towards 
one or more of the four stakeholders in the health system, 
the four ‘p’s, namely the pharmaceutical industry, physicians, 
pharmacists and patients. reference pricing is one such 
measure aimed at the pharmaceutical industry where 
a maximum level of financing is established for a drug in 
comparison with a group of drugs that are considered 
therapeutically equivalent.1
the aims of this study were to explore circumstances that led 
to the introduction of reference pricing for pharmaceuticals 
in malta, to observe systems used locally and to observe 
how these compare with mechanisms in other Eu countries. 
the level of effectiveness and adequacy of these systems 
since their implementation and possible ways of how they 
may be improved were also noted.    
Method  
 
although pricing of medicines in malta is a much discussed 
topic locally, documented information in the context of 
the local scenario is very scarce. to this effect, a qualitative 
study was carried out to obtain a detailed description of 
the subject matter. data was then complemented with 
thematic frameworks, charting and mapping data to make 
it as illustratable as possible. 
a study on 18 interviewees associated with pharmaceutical 
and economical policies was performed.  the population 
considered consisted of relevant local and European 
politicians, high public service officials in their respective 
government departments, local pharmaceutical industry 
representatives, academics and experts in pharmacy and 
economics and relevant opinionists. 
a literature review of 66 articles from the local online 
published media on the subject matter was additionally 
carried out to confirm personal interpretations given by 
such interviewees and fill any information gaps.
the research aims were translated into 7 interview questions, 
piloted and asked to each respondent. similar opinions and 
arguments in different interviews were grouped together 
and quantified. newspaper articles were printed, classified 
and important events were listed in chronological order. 
these were then discussed in relation to the relevant 
interview questions. data from both studies was then 
analysed.  
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Results  
 
the eventuality of an increase in the price of medicines had 
been discussed prior to malta’s accession to the Eu but no 
mechanism was in place to prevent excessive increases in 
prices or to curtail increases once they occurred, resulting in 
reports of medicines’ prices to be considerably higher than 
other Eu member states’ a few years down the line.4
the situation could not be contained owing to several 
factors emanating from the three stakeholders in the 
economic system namely inefficient business environment 
and lack of proper regulation and management on the 
part of government; market failure due to uncompetitive 
practices by medicine importers and lack of a well informed 
and empowered consumer society.  reference pricing was 
introduced as a solution to this problem.
there are essentially 2 systems of reference pricing in malta; 
one for the private market, on a voluntary basis, introduced 
in february 2008 and another for the public sector medicines 
that is obligatory, established in January 2010. the private 
the number of countries used for referencing ranged from 4 to 27 member states.  malta uses 12 reference countries from 
the Eu and the European Economic area (EEa) for the private sector medicines and in the public sector system eleven Eu 
countries are used. 
choice of reference countries was based either on geopolitical factors, including similar size, population and geographical 
positions and historical, political and trade links or on economical factors such as similar gross domestic product (gdp) 
values or baskets of reference countries from low-priced, medium-priced and high-priced countries. malta uses 2 different 
economical systems. a group of countries within 20% points of malta’s gdp per capita in purchasing power standards is 
used for the public reference pricing system whilst a basket of reference pricing mechanism of high, medium and low-
priced countries is used for the private sector system with the selected countries being those where most medicines are 
imported from and the relevant price databases were available.
the price set varied between ex-factory, wholesale and retail prices. in malta the two systems use different pricing policies. 
the private sector system reference price is the average retail price excluding vat calculated by first taking the average 
retail price of each category then taking an average of these averages. the public sector reference price is taken as the 
lowest price from the average wholesale price of the basket of eleven countries, the uK nhs price, government health 
procurement services price, where applicable, and the marketing authorisation holder price.
Table 1: differences in calculating reference price between local system and other Eu countries2,3
sector mechanism applies to all medicines on the private 
market whilst the public service system is applicable only to 
new medicines introduced on the government formulary.
both systems use external reference pricing where prices 
of the drug manufactured by the same company are 
compared across a number of countries, also called ‘cross-
country referencing’. there is however also some degree 
of internal reference pricing within the government 
health system where new medicines introduced on the 
government formulary are compared to others within the 
same therapeutic group already on the formulary.  
comparing these systems together and to those in different 
Eu countries showed that the mechanism of calculating the 
reference price differed in three main aspects (table 1).
out of the 18 respondents interviewed 2 thought the 
system was a success, 6 thought it was not successful and 7 
stated that it had limited success (figure 1).
Figure 1: success of local reference pricing system (n=18)
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the advantages of reference pricing are that it constitutes 
a comparative mechanism where prices of medicines in 
malta could be compared to those in other Eu countries, it 
does not require an intensive or elaborate infrastructure to 
operate, it is a good compromise between government and 
other stakeholders, it is in line with Eu legislation, it has been 
in use for up to 20 years nearly all over Europe and in other 
non-European countries with some measure of success, it 
can reduce inflation and government expenditure and it is 
considered as being better that cost-plus pricing as well as 
bulk buying practices used in the past. 
  
reference pricing however also has its limitations such as 
it may be an arbitrary and artificial concept and cannot 
be considered a fair price. many problems associated with 
pricing of medicines in malta are not being catered for by 
this mechanism such as differential pricing policies set by 
mother companies abroad, doctors’ prescribing habits and 
pro-british tendencies towards branded products, lack of 
reimbursement systems that are usually considered part 
and parcel with reference pricing, restricted medicinal 
entitlement and limited government formulary, inefficient 
and ineffective government purchasing systems, insufficient 
competition leading to manipulation in the private market, 
small volumes and low salaries compared to counterparts 
in other Eu states, high government induced costs such 
as transport, utility, licensing fees and lack of legal back 
up, adequate regulation and enforcement, insufficient 
investment in innovation, limited local industry and high 
level of importation, inadequately informed and socially 
and politically disadvantaged consumers. 
regarding the future of reference pricing in malta the way 
forward could be divided into short, medium and long-term 
measures. short-term measures include acknowledgement 
of problems affecting the pharmaceutical field and 
addressing them in a responsible manner to benefit all 
parties concerned. through consultation processes and tools 
available such as government departments and authorities, 
fora are created for objective information dissemination 
about important matters such as medicines that are 
expensive yet essential to the most vulnerable groups of 
society. reengineering of procurement procedures to 
become efficient and effective,  curtailing of abuses in the 
system such as medicinal entitlement, pilfering and expired 
goods, serious investment in Eu standard warehousing 
and it systems, better management of the government 
formulary and more rational use of medicines ensured.
government-induced costs are to be analysed and revised. 
through competent authorities, barriers to trade such as 
cartels and price fixing and issues constituting such barriers 
should be tackled allowing true market forces to act in 
the longer term. possible measures include liberalisation 
of pharmacies, sale of over-the-counter medications from 
other outlets, competition within retail pharmacies on 
non-medicinals, introduction of full-line wholesalers and 
therapeutic class referencing and tendering. measures to 
actively promote free competition such as incentives to 
local industry, parallel importation and prescription and 
dispensing of generics could be also addressed. 
medium-term measures address future possible courses 
to follow and include fine-tuning the current system, 
introducing more comprehensive changes to address any 
unmet needs, adding more pricing policies or completely 
replacing the current system by a better one. options 
should be studied by government and stakeholders and 
actions for implementation taken accordingly. 
long-term measures aim at considering equity, accessibility 
and sustainability of government health services. the 
current restricted system of entitlement to free medicines 
would have to be reviewed considering options such as 
introducing new chronic conditions in stages or opting 
for more drastic yet more sustainable measures such as 
reimbursement schemes considering also the most socially 
disadvantaged.  other wider perspective options include 
the application of cost-benefit analysis or the concept of 
pay-back mechanisms based on outcome success.
Conclusion  
 
reference pricing systems cannot be considered in a vacuum 
out of context of a holistic and integrated pharmaceutical 
system. lessons must be learnt from the past where systems 
such as medicines registration and the pharmacy of your 
choice scheme could have benefited more from better 
planning prior to their implementation. Economic and 
social impact assessments should be resorted to and results 
used to set up the necessary legislation, clear strategies and 
relevant policies, guidelines and protocols in line with set 
priorities to benefit all those parties involved.  the system 
should be in line with Eu regulations and in the spirit of 
such Eu directives, cater for the specific economical, social, 
and political factors of this country. 
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